Fourier

Analysts: Amgen's PCSK9 didn't cut CV risks enough

Get ready to negotiate, payers: Amgen has its PCSK9 outcomes data. In a long-awaited trial, Repatha cut heart attack risks by 27% and stroke risks by 21%. Will it be enough to rev up a lagging launch?

Tracy Staton Mar 17, 2017 7:38am